Tag: Survival

Most patients who died after withdrawal of life-sustaining therapy were considered to have recovery potential of at least 1 percent

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion

Physical activity attenuates survival disparity between patients with stage III colon cancer and matched population controls

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab

Relative decline seen in cancer mortality among Blacks, but they still have higher mortality rates than Whites

Significant and clinically relevant improvement seen in objective response rate with encorafenib + cetuximab plus mFOLFOX6

Improved overall and lung cancer-specific survival seen for lobectomy, segmentectomy versus wedge resection

Progression-free and overall survival do not differ for patients receiving full-dose, lowered-dose dexamethasone throughout induction

Improved survival seen with perioperative chemotherapy with FLOT versus preoperative chemoradiotherapy

Clinically meaningful improvement seen in progression-free survival for transarterial chemoembolization plus lenvatinib and pembrolizumab